Report Detail

“Human Primary Cells Market” 2018-2026 report is a professional study on the current state of the market that focuses on the major drivers, challenges, opportunities for the leading players. The research report also offers a granular analysis of various definitions, and classification of the industry, applications of the industry, regional breakdown, opportunities, challenges, and chain structure.

About Human Primary Cells Market

Europe Human Primary Cells Market is expected to grow with a CAGR of 6.1% during the forecast period of 2018 to 2025. Europe is a region where strict regulations are implemented for the safety and well-being of any kind of living form. The sedentary lifestyle of people in the region has led to an increase in the prevalence of various curable and non-curable chronic diseases. Several diseases have found to affect the human organ systems such as heart, vascular system, blood, kidneys, skeleton, and musculature. The manipulation of human cells for cell and tissue replacement therapies holds great importance in the treatment of degenerative disease and injuries affecting the human organ systems.

Market Summary:

The Human Primary Cells market is a comprehensive report which offers a meticulous overview of the market share, size, trends, demand, product analysis, application analysis, regional outlook, competitive strategies, forecasts, and strategies impacting the Human Primary Cells Industry. The report includes a detailed analysis of the market competitive landscape, with the help of detailed business profiles, SWOT analysis, project feasibility analysis, and several other details about the key companies operating in the market.

The study on the worldwide Human Primary Cells market strives to offer substantial and profound insights into the current market scenario and the developing growth dynamics. Moreover, the report also provides the market players along with the new contenders a complete view of the market landscape. The inclusive research will enable the well-established as well as the entry-level players to establish their business strategies and accomplish their short-term and long-term goals.

Scope and Segmentation of the Report

The segment analysis is one of the significant sections of this report. Our expert analyst has categorized the market into product type, application/end-user, and geography. All the segments are analyzed based on their market share, growth rate, and growth potential. In the geographical classification, the report highlights the regional markets having high growth potential. This thorough evaluation of the segments would help the players to focus on revenue-generating areas of the Human Primary Cells market.

Based on Type

Blood (peripheral) cells
Endothelial cells
Epithelial cells
Fibroblast cells
Hepatocyte cells
Keratinocyte cells
Melanocyte cells
Pancreatic cells
Smooth muscle cells
Skeletal cells
Adipocyte cells

Based on Application

Medical
Clinical

Regional Analysis

Our analysts are experts in covering all types of geographical markets from developing to mature ones. You can expect a comprehensive research analysis of key regional and country-level markets such as Europe, North America, South America, Asia-Pacific, and the Middle East & Africa. With accurate statistical patterns and regional classification, our domain experts provide you one of the most detailed and easily understandable regional analyses of the Human Primary Cells market.

Competitive Landscape:

The research report also studied the key players operating in the Human Primary Cells market. It has evaluated and explained the research & development stages of these companies, their financial performances, and their expansion plans for the coming years. Moreover, the research report also includes the list of planned initiatives that clearly explain the accomplishments of the companies in the recent past.

Company Coverage (Sales Revenue, Price, Gross Margin, Main Products, etc.):

Lonza
Thermo Fisher Scientific
Sigma-Aldrich
Cell Biologics
Promocell GmbH
Cureline
Zen-Bio
Stemcell Technologies
Cell Applications
Creative Bioarray
Reprocell Europe Ltd
Tebu-Bio

Research Methodology

The research methodology of the market is based on both primary as well as secondary research data sources. It compels different factors affecting the Human Primary Cells industry such as historical data and market trends, different policies of the government, market environment, market risk factors, market restraints, technological advancements, forthcoming innovations, and obstacles in the industry.

The content of the study subjects includes a total of 8 chapters:

Chapter 1, describe the Human Primary Cells market report’s – executive summary, market definition, and market scope. Moreover, the report helps in picking up the crucial information about the said market.

Chapter 2, defines the Research Methodology including primary research, assumptions & exclusions, and secondary data sources. The report follows the simultaneous top-down and bottom approach to provide you the accurate market sizing.

Chapter 3, explains the report segmentation & scope, key market trends (drivers, restraints, and opportunities), along with Porter’s five forces analysis and market share analysis

Chapter 4: It helps in understanding the key product segments and their future of the Human Primary Cells Market. It provides strategic recommendations in key business segments based on the market estimations.

Chapters 5, and 6 to segment the sales by type and application/end-user, with sales market share and growth rate by type, application/end-user, from 2018 to 2016. Our team of Analysts and experts dedicatedly put their effort to provide you the best possible and accurate segmentation data and analysis.

Chapter 7, describes the regional segmentation based on the country level for the forecast period 2018 – 2026. The research report not only provide the market data of the five geographies but also provide the qualitative as well we qualitative information on country level bifurcation.

Chapter 8, to profile the top manufacturers of Human Primary Cells, with price, sales, revenue and market share of Human Primary Cells in 2016, 2017, and 2018. Players are expected to sign acquisition and collaboration deals to expand their products and services portfolio. Such strategic agreements could help them to improve their client base in other countries and gain a competitive advantage


CHAPTER 1. INTRODUCTION

  • 1.1. RESEARCH METHODOLOGY
    • 1.1.1. ERC desk research
    • 1.1.2. ERC data synthesis
    • 1.1.3. Data validation and market feedback
    • 1.1.4. ERC data sources

CHAPTER 2. EUROPE HUMAN PRIMARY CELL MARKET KEY INSIGHTS

  • 2.1. RESEARCH SUMMARY AND SCOPE 25
  • 2.2. HUMAN PRIMARY CELL PRODUCTION (MILLION CELLS), 17–25
    • 2.2.1. Europe Human Primary Cells Production (Million Cells) (17-25)
  • 2.3. HUMAN PRIMARY CELL CONSUMPTION (MILLION CELLS), 17–25
    • 2.3.1. Europe Human Primary Cells Consumption (Million Cells) (17-25)
  • 2.4. HUMAN PRIMARY CELL REVENUE (MILLION USD), 17-25
    • 2.4.1. Europe Human Primary Cells Revenue (Million USD) (17-25)

CHAPTER 3. HUMAN PRIMARY CELL MARKET DYNAMICS

  • 3.1. MARKET DETERMINANTS

CHAPTER 4. EUROPE HUMAN PRIMARY CELL MARKET BY TYPE

  • 4.1. SEGMENT OUTLINE AND MARKET SHARE BY TYPE
  • 4.2. EUROPE HUMAN PRIMARY CELL MARKET REVENUE (MILLION USD) & PRODUCTION VOLUME (CELLS) BY TYPE, 17-25
    • 4.2.1. Europe Human Primary Cell Market Revenue (Million USD) By Type, 17-25
    • 4.2.2. Europe Human Primary Cell Production (Million Cells) By Type, 17-25
  • 4.3. BLOOD (PERIPHERAL) CELLS
    • 4.3.1. Market Growth Indicators
    • 4.3.2. Market Revenue (Million USD), Sales And Production Volume (Million Cells), 17 – 25
  • 4.4. ENDOTHELIAL CELLS
    • 4.4.1. Market Growth Indicators
    • 4.4.2. Market Revenue (Million USD), Sales And Production Volume (Million Cells), 17 – 25
  • 4.5. EPITHELIAL CELLS
    • 4.5.1. Market Growth Indicators
    • 4.5.2. Market Revenue (Million USD), Sales And Production Volume (Million Cells), 17 – 25
  • 4.6. FIBROBLAST CELLS
    • 4.6.1. Market Growth Indicators
    • 4.6.2. Market Revenue (Million USD), Sales And Production Volume (Million Cells), 17 – 25
  • 4.7. HEPACTOCYTE CELLS
    • 4.7.1. Market Growth Indicators
    • 4.7.2. Market Revenue (Million USD), Sales And Production Volume (Million Cells), 17 – 25
  • 4.8. KERATINOCYTE CELLS
    • 4.8.1. Market Growth Indicators
    • 4.8.2. Market Revenue (Million USD), Sales And Production Volume (Million Cells), 17 – 25
  • 4.9. MELANOCYTE CELLS
    • 4.9.1. Market Growth Indicators
    • 4.9.2. Market Revenue (Million USD), Sales And Production Volume (Million Cells), 17 – 25
  • 4.10. PANCREATIC CELLS
    • 4.10.1. Market Growth Indicators
    • 4.10.2. Market Revenue (Million USD), Sales And Production Volume (Million Cells), 17 – 25
  • 4.11. SMOOTH MUSCLE CELLS
    • 4.11.1. Market Growth Indicators
    • 4.11.2. Market Revenue (Million USD), Sales And Production Volume (Million Cells), 17 – 25
  • 4.12. SKELETAL CELLS
    • 4.12.1. Market Growth Indicators
    • 4.12.2. Market Revenue (Million USD), Sales And Production Volume (Million Cells), 17 – 25
  • 4.13. ADIPOCYTE CELLS
    • 4.13.1. Market Growth Indicators
    • 4.13.2. Market Revenue (Million USD), Sales And Production Volume (Million Cells), 17 – 25

CHAPTER 5. EUROPE HUMAN PRIMARY CELL MARKET BY APPLICATION

  • 5.1. SEGMENT OUTLINE AND MARKET SHARE BY APPLICATION 52
  • 5.2. EUROPE HUMAN PRIMARY CELL MARKET REVENUE (MILLION USD) BY APPLICATION, 17-25
  • 5.3. CLINICAL
    • 5.3.1. Market growth indicators
    • 5.3.2. Market revenue (Million USD), 17 – 25
  • 5.4. MEDICAL 55
    • 5.4.1. Market growth indicators
    • 5.4.2. Market revenue (Million USD), 17 – 25
  • 5.5. ESTIMATED SHARE (%) OF HUMAN PRIMARY CELL TYPES IN POTENTIAL APPLICATIONS

CHAPTER 6. EUROPE HUMAN PRIMARY CELL MARKET BY COUNTRIES

  • 6.1. SEGMENT OUTLINE AND MARKET SHARE BY COUNTRIES
  • 6.2. EUROPE HUMAN PRIMARY CELL MARKET REVENUE, PRODUCTION & SALES BY COUNTRIES, 17-25
    • 6.2.1. Europe Human Primary Cell Market Revenue (Million USD) By Countries, 17-25
    • 6.2.2. Europe Human Primary Cell Production (Million Cells) By Countries, 17-25
    • 6.2.3. Europe Human Primary Cell Market Sales (Million Cells) By Countries, 17-25
  • 6.3. GERMANY 63
    • 6.3.1. List of Potential Human Primary Cells Customers in Germany
    • 6.3.2. Germany Human Primary Cell Market Revenue (Million USD), Production (Million Cells) & Sales (Million Cells) By Type, 17-25
    • 6.3.3. Germany Human Primary Cell Revenue (Million USD) And Growth Rate By Type (17-25)
    • 6.3.4. Germany Human Primary Cell Production (Million Cells) And Growth Rate By Type (17-25)
  • 6.4. FRANCE 68
    • 6.4.1. List of Potential Human Primary Cells Customers in France
    • 6.4.2. France Human Primary Cell Market Revenue (Million USD), Production (Million Cells) & Sales (Million Cells) By Type, 17-25
    • 6.4.3. France Human Primary Cell Revenue (Million USD) And Growth Rate By Type (17-25) 71
    • 6.4.4. France Human Primary Cell Production (Million Cells) And Growth Rate By Type (17-25)
  • 6.5. UK
    • 6.5.1. List of Potential Human Primary Cells Customers in UK
    • 6.5.2. UK Human Primary Cell Market Revenue (Million USD), Production (Million Cells) & Sales (Million Cells) By Type, 17-25
    • 6.5.3. UK Human Primary Cell Revenue (Million USD) And Growth Rate By Type (17-25)
    • 6.5.4. UK Human Primary Cell Production (Million Cells) And Growth Rate By Type (17-25)
  • 6.6. ITALY
    • 6.6.1. List of Potential Human Primary Cells Customers in Italy
    • 6.6.2. Italy Human Primary Cell Market Revenue (Million USD), Production (Million Cells) & Sales (Million Cells) By Type, 17-25
    • 6.6.3. Italy Human Primary Cell Revenue (Million USD) And Growth Rate By Type (17-25)
    • 6.6.4. Italy Human Primary Cell Production (Million Cells) And Growth Rate By Type (17-25)
  • 6.7. SPAIN 82
    • 6.7.1. List of Potential Human Primary Cells Customers in Spain
    • 6.7.2. Spain Human Primary Cell Market Revenue (Million USD), Production (Million Cells) & Sales (Million Cells) By Type, 17-25
    • 6.7.3. Spain Human Primary Cell Revenue (Million USD) And Growth Rate By Type (17-25)
    • 6.7.4. Spain Human Primary Cell Production (Million Cells) And Growth Rate By Type (17-25)
  • 6.8. BENELUX 86
    • 6.8.1. List of Potential Human Primary Cells Customers in Benelux
    • 6.8.2. Benelux Human Primary Cell Market Revenue (Million USD), Production (Million Cells) & Sales (Million Cells) By Type, 17-25
    • 6.8.3. Benelux Human Primary Cell Revenue (Million USD) And Growth Rate By Type (17-25)
    • 6.8.4. Benelux Human Primary Cell Production (Million Cells) And Growth Rate By Type (17-25)
  • 6.9. RUSSIA 92
    • 6.9.1. List of Potential Human Primary Cells Customers in Russia
    • 6.9.2. Russia Human Primary Cell Market Revenue (Million USD), Production (Million Cells) & Sales (Million Cells) By Type, 17-25
    • 6.9.3. Russia Human Primary Cell Revenue (Million USD) And Growth Rate By Type (17-25)
    • 6.9.4. Russia Human Primary Cell Production (Million Cells) And Growth Rate By Type (17-25)
  • 6.10. REST OF EUROPE 97
    • 6.10.1. List of Potential Human Primary Cells Customers in Rest of Europe
    • 6.10.2. Rest of Europe Human Primary Cell Market Revenue (Million USD), Production (Million Cells) & Sales (Million Cells) By Type, 17-25
    • 6.10.3. Rest of Europe Human Primary Cell Revenue (Million USD) And Growth Rate By Type (17-25)
    • 6.10.4. Rest of Europe Human Primary Cell Production (Million Cells) And Growth Rate By Type (17-25)

CHAPTER 7. EUROPE HUMAN PRIMARY CELLS MANUFACTURERS PROFILES/ANALYSIS

  • 7.1. LONZA 102
    • 7.1.1. Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
    • 7.1.2. Human Primary Cells Product Category, Application and Specification
      • 7.1.2.1. HUMAN BONE MARROW CD+ PROGENITOR CELLS 103
      • 7.1.2.2. HUMAN PERIPHERAL BLOOD CD14+ MONOCYTES CELLS
      • 7.1.2.3. DERMAL MICROVASCULAR ENDOTHELIAL CELLS
      • 7.1.2.4. HUMAN SKELETAL MUSCLE MYOBLASTS
      • 7.1.2.5. HUMAN LUNG FIBROBLASTS
      • 7.1.2.6. OTHER PRODUCTS
    • 7.1.3. Business Overview
  • 7.2. THERMO FISHER SCIENTIFIC
    • 7.2.1. Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
    • 7.2.2. Human Primary Cells Product Category, Application and Specification
      • 7.2.2.1. Human Mammary Epithelial Cells (HMEC)
      • 7.2.2.2. Human Umbilical Vein Endothelial Cells (HUVEC )
    • 7.2.3. Fibroblasts
    • 7.2.4. Human Skeletal Myoblasts
    • 7.2.5. Human Plateable Hepatocytes, 5-Donor
    • 7.2.6. Other Products
    • 7.2.7. Main Business/Business Overview
  • 7.3. SIGMA-ALDRICH
    • 7.3.1. Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
    • 7.3.2. Human Primary Cells Product Category, Application and Specification
      • 7.3.2.1. Cryoplateable Primary Human Hepatocytes (MTOXH1002)
      • 7.3.2.2. Cryopreserved Primary Human Hepatocytes Juvenile (MTOXH1012)
      • 7.3.2.3. Human Aortic Endothelial Cells (HAOEC)
      • 7.3.2.4. Human Peripheral Blood T Cells (HPBT)
    • 7.3.3. Main Business/Business Overview 109
  • 7.4. CELL BIOLOGICS
    • 7.4.1. Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
    • 7.4.2. Human Primary Cells Product Category, Application and Specification
      • 7.4.2.1. HUMAN PRIMARY AORTIC ENDOTHELIAL CELLS
      • 7.4.2.2. HUMAN PRIMARY AORTIC FIBROBLASTS
      • 7.4.2.3. Human Hepatic Stellate Cells
      • 7.4.2.4. Human Primary Alveolar Epithelial Cells
    • 7.4.3. Main Business/Business Overview
  • 7.5. PROMOCELL GMBH
    • 7.5.1. Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
    • 7.5.2. Human Primary Cells Product Category, Application and Specification
      • 7.5.2.1. Melanocytes
      • 7.5.2.2. Cardiac Myocytes
      • 7.5.2.3. Skeletal Muscle Cells
      • 7.5.2.4. Osteoblasts
    • 7.5.3. Other Products
    • 7.5.4. Main Business/Business Overview
  • 7.6. CURELINE
    • 7.6.1. Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
    • 7.6.2. Human Primary Cells Product Category, Application and Specification
      • 7.6.2.1. Primary Cell Lines
    • 7.6.3. Main Business/Business Overview
  • 7.7. ZEN-BIO 116
    • 7.7.1. Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
    • 7.7.2. Human Primary Cells Product Category, Application and Specification
      • 7.7.2.1. Human Adult Melanocytes
      • 7.7.2.2. Adult Stem Cells
      • 7.7.2.3. Human Dermal Fibroblasts
      • 7.7.2.4. Human Mesothelial Cells
    • 7.7.3. Other Products
    • 7.7.4. Main Business/Business Overview
  • 7.8. STEMCELL TECHNOLOGIES
    • 7.8.1. Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
    • 7.8.2. Human Primary Cells Product Category, Application and Specification
      • 7.8.2.1. Human Peripheral Blood Monocytes
      • 7.8.2.2. Human Platelet Lysate, Fibrinogen-Depleted
      • 7.8.2.3. Human Cord Blood Mononuclear Cells
      • 7.8.2.4. iCell® Cardiac Progenitor Cells
    • 7.8.3. Other Products
    • 7.8.4. Main Business/Business Overview
  • 7.9. CELL APPLICATIONS
    • 7.9.1. Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
    • 7.9.2. Human Primary Cells Product Category, Application and Specification
      • 7.9.2.1. Human Hair Follicle Dermal Papilla Cells
      • 7.9.2.2. Chondrocyte
      • 7.9.2.3. Keratinocyte
    • 7.9.3. Other Products 1
    • 7.9.4. Main Business/Business Overview
  • 7.10. CREATIVE BIOARRAY
    • 7.10.1. COMPANY BASIC INFORMATION, MANUFACTURING BASE, SALES AREA AND ITS COMPETITORS
    • 7.10.2. HUMAN PRIMARY CELLS PRODUCT CATEGORY, APPLICATION AND SPECIFICATION
      • 7.10.2.1. Human Synovial Membrane Fibroblasts
      • 7.10.2.2. Human Leptomeningeal Pericytes
      • 7.10.2.3. ADIPOSE CELLS
      • 7.10.2.4. SKELETAL CELLS
      • 7.10.2.5. PERIPHERAL BLOOD CELLS
    • 7.10.3. Other Products
    • 7.10.4. Main Business/Business Overview
  • 7.11. REPROCELL EUROPE LTD.
    • 7.11.1. COMPANY BASIC INFORMATION, MANUFACTURING BASE, SALES AREA AND ITS COMPETITORS
    • 7.11.2. HUMAN PRIMARY CELLS PRODUCT CATEGORY, APPLICATION AND SPECIFICATION
      • 7.11.2.1. ES/IPS CELLS
      • 7.11.2.2. IMATRIX-2 STEM CELL CULTURE SUBSTRATE
    • 7.11.3. Main Business/Business Overview
  • 7.12. TEBU-BIO
    • 7.12.1. COMPANY BASIC INFORMATION, MANUFACTURING BASE, SALES AREA AND ITS COMPETITORS
    • 7.12.2. HUMAN PRIMARY CELLS PRODUCT CATEGORY, APPLICATION AND SPECIFICATION
      • 7.12.2.1. Human Aortic Endothelial Cells
      • 7.12.2.2. HUMAN BRONCHIAL EPITHELIAL CELL
      • 7.12.2.3. Human SMOOTH MUSCLE CELLS
    • 7.12.3. Other Products
    • 7.12.4. Main Business/Business Overview

CHAPTER 8. MARKET SHARE OF KEY VENDORS

Summary:
Get latest Market Research Reports on Europe Human Primary Cells . Industry analysis & Market Report on Europe Human Primary Cells is a syndicated market report, published as Europe Human Primary Cells Market By Type (Blood (peripheral) cells, Endothelial cells, Epithelial cells, Fibroblast cells, Hepatocyte cells, Keratinocyte cells, Melanocyte cells, Pancreatic cells, Smooth muscle cells, Skeletal cells, Adipocyte cells), By Application (Medical, Clinical), Industry Trends, Estimation & Forecast, 2018 - 2025. It is complete Research Study and Industry Analysis of Europe Human Primary Cells market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

Last updated on

REPORT YOU MIGHT BE INTERESTED

Purchase this Report

$4,700.00
$5,600.00
3,755.30
4,474.40
4,366.30
5,202.40
726,432.00
865,536.00
392,450.00
467,600.00
Credit card Logo

Related Reports


Reason to Buy

Request for Sample of this report